N4P.GB N4 Pharma Plc

TIDMN4P

RNS Number : 6141B

N4 Pharma PLC

04 October 2022

4 October 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Double siRNA Testing Update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R) , a novel delivery system for cancer treatments and vaccines, is pleased to announce successful in vitro testing of Nuvec(R) loaded with two small interfering RNA (siRNA) probes.

On 14 September 2022, the Company announced a strategic update highlighting its intention to focus its further development work on multiple loaded siRNA on Nuvec(R) .

T he Company has now completed initial in vitro testing of Nuvec(R) loaded with two generic siRNA probes, GFP (Green Fluorescent protein) and EHMT-2 (Euchromatic Histone Lysine Methyltransferase 2 ) at the same time. The siRNA probes were loaded onto Nuvec(R) in equal amounts, at a concentration previously shown to be active. Testing demonstrated that both siRNA probes when loaded onto Nuvec(R) were able to significantly silence their respective targets.

Nigel Theobald, Chief Executive Officer of the Company, commented :

"Showing that Nuvec(R) loaded with two generic siRNA probes still achieves significant silencing of their respective genes is validation for us to now begin the further work that we announced on 14 September with EGFR and BCl-2 in a PC9 lung cancer model.

"Achieving the initial successful testing of Nuvec (R) with the generic GFP and EHMT-2 siRNA will also allow us to commence commercial outreach discussions which will only be further strengthened by the results from the new work we are undertaking ."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018.

Enquiries:

 
 N4 Pharma Plc                               Via IFC Advisory 
  Nigel Theobald, CEO 
  Luke Cairns, Executive Director 
 
 SP Angel Corporate Finance LLP              Tel: + 44 (0)20 3470 
  Nominated Adviser and Joint Broker          0470 
  Matthew Johnson/Caroline Rowe (Corporate 
  Finance) 
  Vadim Alexandre/Rob Rees (Corporate 
  Broking) 
 
 IFC Advisory Limited                        Tel: +44 (0)20 3934 
  Financial PR                                6630 
  Graham Herring 
  Zach Cohen 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec(R) .

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCMJBATMTJMBTT

(END) Dow Jones Newswires

October 04, 2022 02:00 ET (06:00 GMT)

N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Fév 2025 à Mar 2025

N4 Pharma (AQSE:N4P.GB)
Graphique Historique de l'Action
De Mar 2024 à Mar 2025